Login Register Cart 0
Generic placeholder image

Recent Patents on Nanotechnology

Editor-in-Chief

ISSN (Print): 1872-2105
ISSN (Online): 2212-4020

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Nanostructured Lipid Carriers (NLCs) as Effective Drug Delivery Systems: Methods of Preparation and their Therapeutic Applications

Author(s): Hind M. Alatawi, Shemah S. Alhwiti, Khwlah A. Alsharif, Shyma S. Albalawi, Shroug M. Abusaleh, Ghada K. Sror and Mona Qushawy*

Volume 18, Issue 2, 2024

Published on: 21 February, 2023

Page: [179 - 189] Pages: 11

DOI: 10.2174/1872210517666230120142439

Price: $65

Abstract

One of the drug delivery technologies is nanostructured lipid carriers (NLCs), which improve drug permeability and thus bioavailability. NLCs are nanoparticles made from a lipid matrix made up of a mixture of solid and liquid lipids. The inclusion of liquid lipids is useful in lowering the ordered structure of solid lipids, increasing nanoparticle loading capacity, and drug entrapment efficiency within NLCs. Hot homogenization, cold homogenization, micro-emulsion, emulsification-solvent diffusion, high shear homogenization, and/or ultrasonication techniques, double emulsion technique, melting dispersion method, membrane contractor technique, and evaporation solvent injection are some of the methods that can be used to make NLCs. Both hydrophilic and lipophilic medicines can be carried out by NLCs. They can deliver medications in a variety of ways, including oral, topical, transdermal, parenteral, and ophthalmic. During the process of preparing this review article, several distinct studies and patent reports about various methods of NLCs formulations, their various therapeutic applications, and various routes of administration were investigated and discussed. The study conducts an in-depth evaluation of the most recent research publications and patents. NLCs have been utilized to treat a variety of disorders, including cancer, fungal infections, bacterial infections, inflammation, liver diseases, and ocular infections, due to their benefits. They can deliver medications to specific locations throughout the body, allowing for drug targeting and a reduction in unwanted side effects. They can also be used to improve bioavailability, reduce the medication's supplied dose, and improve the drug's pharmacological activity.

« Previous Next »
Graphical Abstract

[1]
Janoria KG, Gunda S, Boddu SHS, Mitra AK. Novel approaches to retinal drug delivery. Expert Opin Drug Deliv 2007; 4(4): 371-88.
[http://dx.doi.org/10.1517/17425247.4.4.371] [PMID: 17683251]
[2]
Attama AA. SLN, NLC, LDC: State of the art in drug and active delivery. Recent Pat Drug Deliv Formul 2011; 5(3): 178-87.
[http://dx.doi.org/10.2174/187221111797200524] [PMID: 21834777]
[3]
Kumar R, Dalvi SV, Siril PF. Nanoparticle-based drugs and formulations: current status and emerging applications. ACS Appl Nano Mater 2020; 3(6): 4944-61.
[http://dx.doi.org/10.1021/acsanm.0c00606]
[4]
Gaba B, Fazil M, Ali A, Baboota S, Sahni JK, Ali J. Nanostructured lipid (NLCs) carriers as a bioavailability enhancement tool for oral administration. Drug Deliv 2015; 22(6): 691-700.
[http://dx.doi.org/10.3109/10717544.2014.898110] [PMID: 24670099]
[5]
Thotakura N, Gupta MM, Rajawat JS, Raza K. Promises of lipid-based drug delivery systems in the management of breast cancer. Curr Pharm Des 2021; 27(45): 4568-77.
[http://dx.doi.org/10.2174/1381612827666210728104318] [PMID: 34323182]
[6]
Alshweiat A, Ambrus R, Csóka II. Intranasal nanoparticulate systems as alternative route of drug delivery. Curr Med Chem 2019; 26(35): 6459-92.
[http://dx.doi.org/10.2174/0929867326666190827151741] [PMID: 31453778]
[7]
Mahant S, Rao R, Souto EB, Nanda S. Analytical tools and evaluation strategies for nanostructured lipid carrier-based topical delivery systems. Expert Opin Drug Deliv 2020; 17(7): 963-92.
[http://dx.doi.org/10.1080/17425247.2020.1772750] [PMID: 32441158]
[8]
Hanna PA, Ghorab MM, Gad S. Development of betamethasone dipropionate-loaded nanostructured lipid carriers for topical and transdermal delivery. Antiinflamm Antiallergy Agents Med Chem 2019; 18(1): 26-44.
[http://dx.doi.org/10.2174/1871523017666181115104159] [PMID: 30430947]
[9]
Ahmad J, Rizwanullah M, Amin S, Warsi MH, Ahmad MZ, Barkat MA. Nanostructured lipid carriers (NLCs): Nose-to-brain delivery and theranostic application. Curr Drug Metab 2020; 21(14): 1136-43.
[http://dx.doi.org/10.2174/1389200221666200719003304] [PMID: 32682366]
[10]
Fox CB, Khandhar AP, Hoeven NV. et al. Nanostructured lipid carriers and stable emulsions and uses thereof. WO2018232257A1 2018. Available from: https://patents.google.com/patent/WO2018232257A1/en[2018, accessed 4 June 2022].
[11]
Fuoco D, Cohen J, Rosanelli L. et al.Nanostructure lipid carrier delivery system, composition, and methods. WO2021168573, 2021.
[12]
Harde H, Das M, Jain S. Solid lipid nanoparticles: An oral bioavailability enhancer vehicle. Expert Opin Drug Deliv 2011; 8(11): 1407-24.
[http://dx.doi.org/10.1517/17425247.2011.604311] [PMID: 21831007]
[13]
Movassaghian S, Merkel OM, Torchilin VP. Applications of polymer micelles for imaging and drug delivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2015; 7(5): 691-707.
[http://dx.doi.org/10.1002/wnan.1332] [PMID: 25683687]
[14]
Tapeinos C, Battaglini M, Ciofani G. Advances in the design of solid lipid nanoparticles and nanostructured lipid carriers for targeting brain diseases. J Control Release 2017; 264: 306-32.
[http://dx.doi.org/10.1016/j.jconrel.2017.08.033] [PMID: 28844756]
[15]
Andonova V, Peneva P. Characterization methods for solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC). Curr Pharm Des 2018; 23(43): 6630-42.
[http://dx.doi.org/10.2174/1381612823666171115105721] [PMID: 29141534]
[16]
Shidhaye S, Vaidya R, Sutar S, Patwardhan A, Kadam V. Solid lipid nanoparticles and nanostructured lipid carriers-innovative generations of solid lipid carriers. Curr Drug Deliv 2008; 5(4): 324-31.
[http://dx.doi.org/10.2174/156720108785915087] [PMID: 18855604]
[17]
de Souza ML, dos Santos WM, de Sousa ALMD, et al. Lipid nanoparticles as a skin wound healing drug delivery system: Discoveries and advances. Curr Pharm Des 2020; 26(36): 4536-50.
[http://dx.doi.org/10.2174/1381612826666200417144530] [PMID: 32303163]
[18]
Sawant K, Dodiya S. Recent advances and patents on solid lipid nanoparticles. Recent Pat Drug Deliv Formul 2008; 2(2): 120-35.
[http://dx.doi.org/10.2174/187221108784534081] [PMID: 19075903]
[19]
Naseri N, Valizadeh H, Zakeri-Milani P. Solid lipid nanoparticles and nanostructured lipid carriers: Structure, preparation and application. Adv Pharm Bull 2015; 5(3): 305-13.
[http://dx.doi.org/10.15171/apb.2015.043] [PMID: 26504751]
[20]
Fang C-L, Al-Suwayeh SA, Fang JY. Nanostructured lipid carriers (NLCs) for drug delivery and targeting. Recent Pat Nanotechnol 2013; 7(1): 41-55.
[http://dx.doi.org/10.2174/187221013804484827] [PMID: 22946628]
[21]
Müller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev 2002; 54(S1): S131-55.
[http://dx.doi.org/10.1016/S0169-409X(02)00118-7] [PMID: 12460720]
[22]
Battaglia L, Gallarate M. Lipid nanoparticles: State of the art, new preparation methods and challenges in drug delivery. Expert Opin Drug Deliv 2012; 9(5): 497-508.
[http://dx.doi.org/10.1517/17425247.2012.673278] [PMID: 22439808]
[23]
Dobreva M, Stefanov S, Andonova V. Natural lipids as structural components of solid lipid nanoparticles and nanostructured lipid carriers for topical delivery. Curr Pharm Des 2020; 26(36): 4524-35.
[http://dx.doi.org/10.2174/1381612826666200514221649] [PMID: 32410552]
[24]
Seabra CL, Pinho C, Rodrigues M, et al. Nanostructurated lipid carriers, methods and uses thereof. EP3474864A1, 2019. Available from: https://patents.google.com/patent/EP3474864A1/en
[25]
Delmas T, Fraichard A, Bayle PA, et al. Encapsulation and release behavior from lipid nanoparticles: Model study with nile red fluorophore. J Colloid Sci Biotechnol 2012; 1(1): 16-25.
[http://dx.doi.org/10.1166/jcsb.2012.1010]
[26]
Shah R, Eldridge D, Palombo E, et al. Lipid nanoparticles: Production, characterization and stability Composition and structure. Springer 2015; pp. 11-22.
[27]
Tamjidi F, Shahedi M, Varshosaz J, Nasirpour A. Nanostructured lipid carriers (NLC): A potential delivery system for bioactive food molecules. Innov Food Sci Emerg Technol 2013; 19: 29-43.
[http://dx.doi.org/10.1016/j.ifset.2013.03.002]
[28]
Purohit DK. Nano-lipid carriers for topical application: Current scenario. Asian J Pharm AJP Free Full Text Artic Asian J Pharm 2016; 10(1)
[http://dx.doi.org/10.22377/ajp.v10i1.544]
[29]
Subramaniam B, Siddik ZH, Nagoor NH. Optimization of nanostructured lipid carriers: understanding the types, designs, and parameters in the process of formulations. J Nanopart Res 2020; 22(6): 141.
[http://dx.doi.org/10.1007/s11051-020-04848-0]
[30]
Kharat M, McClements DJ. Fabrication and characterization of nanostructured lipid carriers (NLC) using a plant-based emulsifier: Quillaja saponin. Food Res Int 2019; 126: 108601.
[http://dx.doi.org/10.1016/j.foodres.2019.108601] [PMID: 31732055]
[31]
Garcês A, Amaral MH, Sousa Lobo JM, Silva AC. Formulations based on solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for cutaneous use: A review. Eur J Pharm Sci 2018; 112: 159-67.
[http://dx.doi.org/10.1016/j.ejps.2017.11.023] [PMID: 29183800]
[32]
Mo Z, Ban J, Zhang Y, et al. Nanostructured lipid carriers-based thermosensitive eye drops for enhanced, sustained delivery of dexamethasone. Nanomedicine 2018; 13(11): 1239-53.
[http://dx.doi.org/10.2217/nnm-2017-0318] [PMID: 29949466]
[33]
Yoon G, Park JW, Yoon IS. Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs): recent advances in drug delivery. J Pharm Investig 2013; 43(5): 353-62.
[http://dx.doi.org/10.1007/s40005-013-0087-y]
[34]
Niezgoda N, Gliszczyńska A, Kulbacka j. Nanostructured lipid carriers stabilized with phosphatidylcholine and method of their preparation. PL430302, 2020.
[35]
Muchow M, Maincent P, Müller RH. Lipid nanoparticles with a solid matrix (SLN, NLC, LDC) for oral drug delivery. Drug Dev Ind Pharm 2008; 34(12): 1394-405.
[http://dx.doi.org/10.1080/03639040802130061] [PMID: 18665980]
[36]
Muhindo D, Ashour EA, Almutairi M, Joshi PH, Repka MA. Continuous production of raloxifene hydrochloride loaded nanostructured lipid carriers using hot-melt extrusion technology. J Drug Deliv Sci Technol 2021; 65: 102673.
[http://dx.doi.org/10.1016/j.jddst.2021.102673] [PMID: 34306183]
[37]
Souto EB, Müller RH. Investigation of the factors influencing the incorporation of clotrimazole in SLN and NLC prepared by hot high-pressure homogenization. J Microencapsul 2006; 23(4): 377-88.
[http://dx.doi.org/10.1080/02652040500435295] [PMID: 16854814]
[38]
Prabahar K, Udhumansha U, Elsherbiny N, Qushawy M. Microneedle mediated transdermal delivery of β-sitosterol loaded nanostructured lipid nanoparticles for androgenic alopecia. Drug Deliv 2022; 29(1): 3022-34.
[http://dx.doi.org/10.1080/10717544.2022.2120927] [PMID: 36110028]
[39]
Kushwaha SKS, Kumar V, Mantry S, et al. Desvenlafaxine succinate loaded nanostructured lipid carrier (nlc) for brain targeting via nasal route. AU2021104270, 2021.
[40]
Duong VA, Nguyen T-T-L, Maeng H-J, Chi S-C. Nanostructured lipid carriers containing ondansetron hydrochloride by cold high-pressure homogenization method: Preparation, characterization, and pharmacokinetic evaluation. J Drug Deliv Sci Technol 2019; 53: 101185.
[http://dx.doi.org/10.1016/j.jddst.2019.101185]
[41]
Kim CH, Kang TH, Kim BD, et al. Enhanced docetaxel delivery using sterically stabilized RIPL peptide-conjugated nanostructured lipid carriers: In vitro and in vivo antitumor efficacy against SKOV3 ovarian cancer cells. Int J Pharm 2020; 583: 119393.
[http://dx.doi.org/10.1016/j.ijpharm.2020.119393] [PMID: 32376445]
[42]
Khan AS, ud Din F, Ali Z, et al. Development, in vitro and in vivo evaluation of miltefosine loaded nanostructured lipid carriers for the treatment of cutaneous leishmaniasis. Int J Pharm 2021; 593: 120109.
[http://dx.doi.org/10.1016/j.ijpharm.2020.120109] [PMID: 33253802]
[43]
Qidwai A, Khan S, Md S, et al. Nanostructured lipid carrier in photodynamic therapy for the treatment of basal-cell carcinoma. Drug Deliv 2016; 23(4): 1476-85.
[http://dx.doi.org/10.3109/10717544.2016.1165310] [PMID: 26978275]
[44]
Li Q, Cai T, Huang Y, Xia X, Cole S, Cai Y. A review of the structure, preparation, and application of NLCs, PNPs, and PLNs. Nanomaterials 2017; 7(6): 122.
[http://dx.doi.org/10.3390/nano7060122] [PMID: 28554993]
[45]
Liu CH, Wu CT. Optimization of nanostructured lipid carriers for lutein delivery. Colloids Surf A Physicochem Eng Asp 2010; 353(2-3): 149-56.
[http://dx.doi.org/10.1016/j.colsurfa.2009.11.006]
[46]
Duong VA, Nguyen TTL, Maeng HJ, Chi SC. Preparation of ondansetron hydrochloride-loaded nanostructured lipid carriers using solvent injection method for enhancement of pharmacokinetic properties. Pharm Res 2019; 36(10): 138.
[http://dx.doi.org/10.1007/s11095-019-2672-x] [PMID: 31350675]
[47]
D SN. Patel DMM. Preparation and evaluation of 5-florouracil loaded nano-structured lipid carrier by double emulsification techniques. Am J Pharm Tech Res 2019; 9(4): 177-209.
[http://dx.doi.org/10.46624/ajptr.2019.v9.i4.014]
[48]
Emami J, Rezazadeh M, Varshosaz J, Tabbakhian M, Aslani A. Formulation of LDL targeted nanostructured lipid carriers loaded with paclitaxel: A detailed study of preparation, freeze drying condition, and in vitro cytotoxicity. J Nanomater 2012; 2012: 1-10.
[http://dx.doi.org/10.1155/2012/358782]
[49]
Tavakoli N, Taymouri S, Saeidi A, Akbari V. Thermosensitive hydrogel containing sertaconazole loaded nanostructured lipid carriers for potential treatment of fungal keratitis. Pharm Dev Technol 2019; 24(7): 891-901.
[http://dx.doi.org/10.1080/10837450.2019.1616755] [PMID: 31062987]
[50]
Uprit S, Kumar Sahu R, Roy A, Pare A. Preparation and characterization of minoxidil loaded nanostructured lipid carrier gel for effective treatment of alopecia. Saudi Pharm J 2013; 21(4): 379-85.
[http://dx.doi.org/10.1016/j.jsps.2012.11.005] [PMID: 24227958]
[51]
Almeida H, Lobão P, Frigerio C, et al. Preparation, characterization and biocompatibility studies of thermoresponsive eyedrops based on the combination of nanostructured lipid carriers (NLC) and the polymer Pluronic F-127 for controlled delivery of ibuprofen. Pharm Dev Technol 2017; 22(3): 336-49.
[http://dx.doi.org/10.3109/10837450.2015.1125922] [PMID: 28240141]
[52]
Chauhan I, Yasir M, Verma M, Singh AP. Nanostructured lipid carriers: A groundbreaking approach for transdermal drug delivery. Adv Pharm Bull 2020; 10(2): 150-65.
[http://dx.doi.org/10.34172/apb.2020.021] [PMID: 32373485]
[53]
Souto EB, Wissing SA, Barbosa CM, Müller RH. Evaluation of the physical stability of SLN and NLC before and after incorporation into hydrogel formulations. Eur J Pharm Biopharm 2004; 58(1): 83-90.
[http://dx.doi.org/10.1016/j.ejpb.2004.02.015] [PMID: 15207541]
[54]
Shelar DB, Pawar SK, Vavia PR. Fabrication of isradipine nanosuspension by anti-solvent microprecipitation–high-pressure homogenization method for enhancing dissolution rate and oral bioavailability. Drug Deliv Transl Res 2013; 3(5): 384-91.
[http://dx.doi.org/10.1007/s13346-012-0081-3] [PMID: 25788346]
[55]
Garud A, Singh D, Garud N. Solid lipid nanoparticles (SLN): Method, characterization and applications. Int Curr Pharm J 2012; 1(11): 384-93.
[http://dx.doi.org/10.3329/icpj.v1i11.12065]
[56]
Mukherjee S, Ray S, Thakur RS. Solid lipid nanoparticles: A modern formulation approach in drug delivery system. Indian J Pharm Sci 2009; 71(4): 349-58.
[http://dx.doi.org/10.4103/0250-474X.57282] [PMID: 20502539]
[57]
Luo Q, Zhao J, Zhang X, Pan W. Nanostructured lipid carrier (NLC) coated with Chitosan Oligosaccharides and its potential use in ocular drug delivery system. Int J Pharm 2011; 403(1-2): 185-91.
[http://dx.doi.org/10.1016/j.ijpharm.2010.10.013] [PMID: 20951778]
[58]
Fritz G, Schädler V, Willenbacher N, Wagner NJ. Electrosteric stabilization of colloidal dispersions. Langmuir 2002; 18(16): 6381-90.
[http://dx.doi.org/10.1021/la015734j]
[59]
Bunjes H, Unruh T. Characterization of lipid nanoparticles by differential scanning calorimetry, X-ray and neutron scattering. Adv Drug Deliv Rev 2007; 59(6): 379-402.
[http://dx.doi.org/10.1016/j.addr.2007.04.013] [PMID: 17658653]
[60]
Chen Y, Zhou L, Yuan L, Zhang ZH, Liu X, Wu Q. Formulation, characterization, and evaluation of in vitro skin permeation and in vivo pharmacodynamics of surface-charged tripterine-loaded nanostructured lipid carriers. Int J Nanomedicine 2012; 7: 3023-32.
[PMID: 22787398]
[61]
Houacine C, Adams D, Singh KK. Impact of liquid lipid on development and stability of trimyristin nanostructured lipid carriers for oral delivery of resveratrol. J Mol Liq 2020; 316: 113734.
[http://dx.doi.org/10.1016/j.molliq.2020.113734]
[62]
Tsai MJ, Wu PC, Huang YB, et al. Baicalein loaded in tocol nanostructured lipid carriers (tocol NLCs) for enhanced stability and brain targeting. Int J Pharm 2012; 423(2): 461-70.
[http://dx.doi.org/10.1016/j.ijpharm.2011.12.009] [PMID: 22193056]
[63]
Das S, Ng WK, Tan RBH. Are nanostructured lipid carriers (NLCs) better than solid lipid nanoparticles (SLNs): Development, characterizations and comparative evaluations of clotrimazole-loaded SLNs and NLCs? Eur J Pharm Sci 2012; 47(1): 139-51.
[http://dx.doi.org/10.1016/j.ejps.2012.05.010] [PMID: 22664358]
[64]
Klang V, Valenta C, Matsko NB. Electron microscopy of pharmaceutical systems. Micron 2013; 44: 45-74.
[http://dx.doi.org/10.1016/j.micron.2012.07.008] [PMID: 22921788]
[65]
Mishra RK, Ahmad A, Kumar A, Vyawahare A, Raza SS, Khan R. Lipid-based nanocarrier-mediated targeted delivery of celecoxib attenuate severity of ulcerative colitis. Mater Sci Eng C 2020; 116: 111103.
[http://dx.doi.org/10.1016/j.msec.2020.111103] [PMID: 32806257]
[66]
Qushawy M. Effect of the surfactant and liquid lipid type in the physico-chemical characteristics of beeswax-based nanostructured lipid carrier (NLC) of metformin. Pharm Nanotechnol 2021; 9(3): 200-9.
[http://dx.doi.org/10.2174/2211738509666210222143716] [PMID: 33618652]
[67]
Üner M. Preparation, characterization and physico-chemical properties of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC): Their benefits as colloidal drug carrier systems. Pharmazie 2006; 61(5): 375-86.
[PMID: 16724531]
[68]
Han F, Li S, Yin R, Liu H, Xu L. Effect of surfactants on the formation and characterization of a new type of colloidal drug delivery system: Nanostructured lipid carriers. Colloids Surf A Physicochem Eng Asp 2008; 315(1-3): 210-6.
[http://dx.doi.org/10.1016/j.colsurfa.2007.08.005]
[69]
Garg NK, Sharma G, Singh B, et al. Quality by Design (QbD)-enabled development of aceclofenac loaded-nano structured lipid carriers (NLCs): An improved dermatokinetic profile for inflammatory disorder(s). Int J Pharm 2017; 517(1-2): 413-31.
[http://dx.doi.org/10.1016/j.ijpharm.2016.12.010] [PMID: 27956192]
[70]
Abdelbary G, Haider M. In vitro characterization and growth inhibition effect of nanostructured lipid carriers for controlled delivery of methotrexate. Pharm Dev Technol 2013; 18(5): 1159-68.
[http://dx.doi.org/10.3109/10837450.2011.614251] [PMID: 21958084]
[71]
Haider M, Abdin SM, Kamal L, Orive G. Nanostructured lipid carriers for delivery of chemotherapeutics: A review. Pharmaceutics 2020; 12(3): 288.
[http://dx.doi.org/10.3390/pharmaceutics12030288] [PMID: 32210127]
[72]
Doktorovova S, Souto EB. Nanostructured lipid carrier-based hydrogel formulations for drug delivery: A comprehensive review. Expert Opin Drug Deliv 2009; 6(2): 165-76.
[http://dx.doi.org/10.1517/17425240802712590] [PMID: 19239388]
[73]
Jain S, Patel N, Shah MK, Khatri P, Vora N. Recent advances in lipid-based vesicles and particulate carriers for topical and transdermal application. J Pharm Sci 2017; 106(2): 423-45.
[http://dx.doi.org/10.1016/j.xphs.2016.10.001] [PMID: 27865609]
[74]
Sachdeva MS, Patlolla R. Nanoparticle formulations for skin delivery. US8715736B2, 2014.
[75]
Alam S, Aslam M, Khan A, et al. Nanostructured lipid carriers of pioglitazone for transdermal application: From experimental design to bioactivity detail. Drug Deliv 2016; 23(2): 601-9.
[http://dx.doi.org/10.3109/10717544.2014.923958] [PMID: 24937378]
[76]
Liu D, Liu Z, Wang L, Zhang C, Zhang N. Nanostructured lipid carriers as novel carrier for parenteral delivery of docetaxel. Colloids Surf B Biointerfaces 2011; 85(2): 262-9.
[http://dx.doi.org/10.1016/j.colsurfb.2011.02.038] [PMID: 21435845]
[77]
Lin Y-K, Huang Z-R, Zhuo R-Z, Fang JY. Combination of calcipotriol and methotrexate in nanostructured lipid carriers for topical delivery. Int J Nanomedicine 2010; 5: 117-28.
[PMID: 20309398]
[78]
Ranpise HA, Gujar KN, Pawar SC, et al. Formulation, optimization, and evaluation of ketoconazole loaded nanostructured lipid carrier gel for topical delivery. Drug Deliv Lett 2020; 10(1): 61-71.
[http://dx.doi.org/10.2174/2210303109666190717155731]
[79]
Yazdani AS, Ahmad NS, Naeimifar A, et al. Preparation and safety evaluation of topical simvastatin loaded nlcs for vitiligo. Adv Pharm Bull 2020; 11(1): 104-10.
[http://dx.doi.org/10.34172/apb.2021.011] [PMID: 33747857]
[80]
Cho CW, Na YG, Lee HK, et al. Nanostructured lipid carriers comprising econazole and film-forming topical pharmaceutical composition containing the same. KR20200117345, 2020.
[81]
Sharma N, Kumar S, Joshi G, Choudhary D. Formulation and characterization of febuxostat loaded nanostructured lipid carriers (NLCs)-gel for topical treatment of gout. Recent Pat Nanotechnol 2022; 16(3): 250-8.
[http://dx.doi.org/10.2174/1872210515666210415114118] [PMID: 33858317]
[82]
Singh MR, Singh D, Sahu KK, et al. A method of preparation of triamcinolone acetonide encapsulated nanostructured lipid carriers for psoriasis treatment. AU2021106678, 2021.
[83]
Özdemir S, Çelik B, Üner M. Properties and therapeutic potential of solid lipid nanoparticles and nanostructured lipid carriers as promising colloidal drug delivery systems Materials for Biomedical Engineering. Elsevier 2019; pp. 457-505.
[http://dx.doi.org/10.1016/B978-0-12-816913-1.00015-5]
[84]
Jaiswal P, Gidwani B, Vyas A. Nanostructured lipid carriers and their current application in targeted drug delivery. Artif Cells Nanomed Biotechnol 2016; 44(1): 27-40.
[http://dx.doi.org/10.3109/21691401.2014.909822] [PMID: 24813223]
[85]
Shahbazi M-A, Santos HA. Improving oral absorption via drug-loaded nanocarriers: absorption mechanisms, intestinal models and rational fabrication. Curr Drug Metab 2013; 14(1): 28-56.
[http://dx.doi.org/10.2174/138920013804545133] [PMID: 22497568]
[86]
Poonia N, Kharb R, Lather V, Pandita D. Nanostructured lipid carriers: Versatile oral delivery vehicle. Future Sci OA 2016; 2(3): FSO135.
[http://dx.doi.org/10.4155/fsoa-2016-0030] [PMID: 28031979]
[87]
Yu Q, Hu X, Ma Y, et al. Lipids-based nanostructured lipid carriers (NLCs) for improved oral bioavailability of sirolimus. Drug Deliv 2016; 23(4): 1469-75.
[http://dx.doi.org/10.3109/10717544.2016.1153744] [PMID: 27187522]
[88]
Bondi’ ML, Giammona G, Craparo EF, et al. Nanostructured lipid carriers containing riluzole and phamaceutical formulations containing said particles. US20100247619A1, 2010.
[89]
Agarwal S. HariKumar SL, Negi P, Upadhyay N, Garg R. Quetiapine fumarate loaded nanostructured lipid carrier for enhancing oral bioavailability: Design, development and pharmacokinetic assessment. Curr Drug Deliv 2021; 18(2): 184-98.
[http://dx.doi.org/10.2174/15672018MTA4cNTc6w] [PMID: 32723273]
[90]
Tarhan O, Spotti MJ. Nutraceutical delivery through nano-emulsions: General aspects, recent applications and patented inventions. Colloids Surf B Biointerfaces 2021; 200: 111526.
[http://dx.doi.org/10.1016/j.colsurfb.2020.111526] [PMID: 33517153]
[91]
Nimtrakul P, Tiyaboonchai W, Lamlertthon S, Amphotericin B. Amphotericin b loaded nanostructured lipid carriers for parenteral delivery: Characterization, antifungal and in vitro toxicity assessment. Curr Drug Deliv 2019; 16(7): 645-53.
[http://dx.doi.org/10.2174/1567201816666190729145223] [PMID: 31362675]
[92]
Galvão JG, Santos RL, Silva ARST, et al. Carvacrol loaded nanostructured lipid carriers as a promising parenteral formulation for leishmaniasis treatment. Eur J Pharm Sci 2020; 150: 105335.
[http://dx.doi.org/10.1016/j.ejps.2020.105335] [PMID: 32272211]
[93]
Jia L, Zhang D, Li Z, et al. Nanostructured lipid carriers for parenteral delivery of silybin: Biodistribution and pharmacokinetic studies. Colloids Surf B Biointerfaces 2010; 80(2): 213-8.
[http://dx.doi.org/10.1016/j.colsurfb.2010.06.008] [PMID: 20621458]
[94]
Maulvi FA, Shetty KH, Desai DT, Shah DO, Willcox MDP. Recent advances in ophthalmic preparations: Ocular barriers, dosage forms and routes of administration. Int J Pharm 2021; 608: 121105.
[http://dx.doi.org/10.1016/j.ijpharm.2021.121105] [PMID: 34537269]
[95]
Seyfoddin A, Al-Kassas R. Development of solid lipid nanoparticles and nanostructured lipid carriers for improving ocular delivery of acyclovir. Drug Dev Ind Pharm 2013; 39(4): 508-19.
[http://dx.doi.org/10.3109/03639045.2012.665460] [PMID: 22424312]
[96]
Varela-Fernández R, García-Otero X, Díaz-Tomé V, et al. Lactoferrin-loaded nanostructured lipid carriers (NLCs) as a new formulation for optimized ocular drug delivery. Eur J Pharm Biopharm 2022; 172: 144-56.
[http://dx.doi.org/10.1016/j.ejpb.2022.02.010] [PMID: 35183717]
[97]
Iqbal MA, Md S, Sahni JK, Baboota S, Dang S, Ali J. Nanostructured lipid carriers system: Recent advances in drug delivery. J Drug Target 2012; 20(10): 813-30.
[http://dx.doi.org/10.3109/1061186X.2012.716845] [PMID: 22931500]
[98]
Moreno-Sastre M, Pastor M, Esquisabel A, et al. Pulmonary delivery of tobramycin-loaded nanostructured lipid carriers for Pseudomonas aeruginosa infections associated with cystic fibrosis. Int J Pharm 2016; 498(1-2): 263-73.
[http://dx.doi.org/10.1016/j.ijpharm.2015.12.028] [PMID: 26705155]
[99]
Taratula O, Kuzmov A, Shah M, Garbuzenko OB, Minko T. Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA. J Control Release 2013; 171(3): 349-57.
[http://dx.doi.org/10.1016/j.jconrel.2013.04.018] [PMID: 23648833]
[100]
Patlolla RR, Chougule M, Patel AR, Jackson T, Tata PNV, Singh M. Formulation, characterization and pulmonary deposition of nebulized celecoxib encapsulated nanostructured lipid carriers. J Control Release 2010; 144(2): 233-41.
[http://dx.doi.org/10.1016/j.jconrel.2010.02.006] [PMID: 20153385]
[101]
Pardeike J, Weber S, Zarfl HP, Pagitz M, Zimmer A. Itraconazole-loaded nanostructured lipid carriers (NLC) for pulmonary treatment of aspergillosis in falcons. Eur J Pharm Biopharm 2016; 108: 269-76.
[http://dx.doi.org/10.1016/j.ejpb.2016.07.018] [PMID: 27449629]
[102]
Souto EB, Müller RH. Cosmetic features and applications of lipid nanoparticles (SLN ®, NLC ®). Int J Cosmet Sci 2008; 30(3): 157-65.
[http://dx.doi.org/10.1111/j.1468-2494.2008.00433.x] [PMID: 18452432]
[103]
Gan L, Deng J, Hu L, Lu W, Cui D, Zhang W. The microstructure of nanocarrier system and its application in cosmetics. Nano Life 2020; 10(4): 2040012.
[http://dx.doi.org/10.1142/S1793984420400127]
[104]
Loo Ch, Basri M, Ismail R, et al. Effect of compositions in nanostructured lipid carriers (NLC) on skin hydration and occlusion. Int J Nanomedicine 2013; 8: 13-22.
[PMID: 23293516]
[105]
Chu CC, Tan CP, Nyam KL. Development of nanostructured lipid carriers (nlcs) using pumpkin and kenaf seed oils with potential photoprotective and antioxidative properties. Eur J Lipid Sci Technol 2019; 121(10): 1900082.
[http://dx.doi.org/10.1002/ejlt.201900082]
[106]
Tarimci MN, Ozturk C, Amasya G, et al. Semi-solid nanostructured lipid carrier (nlc) formulation for cosmetic products. WO2022005431, 2022.
[107]
Song S, Mao G, Du J, Zhu X. Novel RGD containing, temozolomide-loading nanostructured lipid carriers for glioblastoma multiforme chemotherapy. Drug Deliv 2016; 23(4): 1404-8.
[http://dx.doi.org/10.3109/10717544.2015.1064186] [PMID: 26203687]
[108]
Pinheiro VCS, Caria CPAA, Martins SDSJJ, et al. Nanostructured drug delivery system as a multifunctional platform for therapy. WO2021111364, 2021.
[109]
Chand P, Kumar H, Badduri N, et al. Design and evaluation of cabazitaxel loaded NLCs against breast cancer cell lines. Colloids Surf B Biointerfaces 2021; 199: 111535.
[http://dx.doi.org/10.1016/j.colsurfb.2020.111535] [PMID: 33360926]
[110]
Zhang X, Gan Y, Gan L, Nie S, Pan W. PEGylated nanostructured lipid carriers loaded with 10-hydroxycamptothecin: an efficient carrier with enhanced anti-tumour effects against lung cancer. J Pharm Pharmacol 2010; 60(8): 1077-87.
[http://dx.doi.org/10.1211/jpp.60.8.0014] [PMID: 18644200]
[111]
Gundogdu E, Demir ES, Ekinci M, et al. An innovative formulation based on nanostructured lipid carriers for imatinib delivery: Pre-formulation, cellular uptake and cytotoxicity studies. Nanomaterials 2022; 12(2): 250.
[http://dx.doi.org/10.3390/nano12020250] [PMID: 35055267]
[112]
Nayerossadat N, Ali PA, Maedeh T. Viral and nonviral delivery systems for gene delivery. Adv Biomed Res 2012; 1(1): 27.
[http://dx.doi.org/10.4103/2277-9175.98152] [PMID: 23210086]
[113]
Alenzi AM, Albalawi SA, Alghamdi SG, Albalawi RF, Albalawi HS, Qushawy M. Review on different vesicular drug delivery systems (vddss) and their applications. Recent Pat Nanotechnol 2022; 16: 28.
[http://dx.doi.org/10.2174/1872210516666220228150624] [PMID: 35227188]
[114]
Zhang B, Zhang Y, Yu D. Lung cancer gene therapy: Transferrin and hyaluronic acid dual ligand-decorated novel lipid carriers for targeted gene delivery. Oncol Rep 2017; 37(2): 937-44.
[http://dx.doi.org/10.3892/or.2016.5298] [PMID: 27959442]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy